Baxter International Inc. has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A. for $900 million, gaining the leading biologic treatment Oncaspar, the investigational calaspargase pegol, and an established oncology infrastructure with clinical and sales resources. The transaction is expected to close in the third quarter. By mid-year, Baxter expects to establish the BioScience business as a separate biopharma company, Baxalta...